![Open access](/images/ico/o.png)
![](/images/ico/ico5.png)
Author: Kocoglu Mehmet Badros Ashraf
Publisher: MDPI
E-ISSN: 1424-8247|9|1|3-3
ISSN: 1424-8247
Source: Pharmaceuticals, Vol.9, Iss.1, 2016-01, pp. : 3-3
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/o.png)
![](/images/ico/ico5.png)
![](/images/ico/o.png)
![](/images/ico/ico5.png)
![](/images/ico/o.png)
![](/images/ico/ico5.png)
Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
Pharmaceuticals, Vol. 3, Iss. 4, 2010-04 ,pp. :
![](/images/ico/o.png)
![](/images/ico/ico5.png)
Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
By Merin Noah M. Kelly Kevin R.
Pharmaceuticals, Vol. 8, Iss. 1, 2014-12 ,pp. :